Edwards Lifesciences Corporation EW NYSE

Edwards Lifesciences Corporation (EW) generated $1.6B in operating cash flow for fiscal year 2025. After capital expenditures of $260.2M, free cash flow was $1.34B.

Free cash flow margin was 22% of revenue. Cash conversion ratio was 1.49x, indicating earnings are backed by cash.

The company returned $893.4M in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (76/100, Pass) — $1.34B (22% FCF margin) supports a durable competitive advantage
• INCOME (70/100) — Cash conversion ratio was 1.49x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 74/100 with 6/7 criteria passed.